Medical Economics December 2, 2024
Richard Payerchin

Key Takeaways

  • Side effects of GLP-1 RA drugs influence patient adherence, despite controlled research guiding physicians.
  • Real-world experiences may lead to treatment discontinuation due to physical side effects.
  • Cost and availability significantly impact patient willingness to continue treatment.
  • Robert Kushner, MD, highlights these factors based on his expertise in obesity and nutrition.

A physician researcher and author discusses the latest information on GLP-1 RA antiobesity medications.

Side effects play a role in a patient’s desire to use GLP-1 RA drugs for weight loss or other health conditions....

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Conferences / Podcast, Pharma / Biotech, Physician, Provider, Trends
AbbVie Enters Obesity Field, Paying $350M for Amylin Receptor Agonist Already in the Clinic
2025 Drugs to Watch: Market Access, Innovation, and the Future of Reimbursement
Renowned Geneticist Francis Collins, MD, PhD, Retires from NIH
How AI Is Transforming The Pharmaceutical Industry
MHE Week in Review – Medicaid Cuts, Congressional PBM Hearing and More

Share This Article